Hologic, Inc. $HOLX Shares Sold by Curbstone Financial Management Corp

Curbstone Financial Management Corp decreased its position in Hologic, Inc. (NASDAQ:HOLX) by 5.3% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 22,146 shares of the medical equipment provider’s stock after selling 1,250 shares during the quarter. Curbstone Financial Management Corp’s holdings in Hologic were worth $1,443,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of HOLX. Victory Capital Management Inc. increased its stake in shares of Hologic by 34.4% during the 1st quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider’s stock valued at $408,283,000 after acquiring an additional 1,692,177 shares during the last quarter. Allspring Global Investments Holdings LLC grew its holdings in shares of Hologic by 473.5% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 1,701,820 shares of the medical equipment provider’s stock worth $111,180,000 after purchasing an additional 1,405,085 shares during the period. Nuance Investments LLC grew its holdings in shares of Hologic by 623.7% during the 1st quarter. Nuance Investments LLC now owns 1,081,333 shares of the medical equipment provider’s stock worth $66,794,000 after purchasing an additional 931,920 shares during the period. Invesco Ltd. grew its holdings in shares of Hologic by 18.8% during the 1st quarter. Invesco Ltd. now owns 4,834,957 shares of the medical equipment provider’s stock worth $298,655,000 after purchasing an additional 764,573 shares during the period. Finally, Nuveen LLC purchased a new stake in shares of Hologic during the 1st quarter worth about $30,317,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Price Performance

Shares of NASDAQ HOLX opened at $69.85 on Friday. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $84.39. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. The business’s fifty day moving average price is $67.11 and its two-hundred day moving average price is $63.51. The firm has a market capitalization of $15.54 billion, a PE ratio of 28.98, a P/E/G ratio of 2.35 and a beta of 0.63.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, beating analysts’ consensus estimates of $1.05 by $0.03. The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The company’s quarterly revenue was up 1.2% compared to the same quarter last year. During the same period last year, the company earned $1.06 earnings per share. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, research analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Insiders Place Their Bets

In other Hologic news, CEO Stephen P. Macmillan sold 138,358 shares of the firm’s stock in a transaction dated Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the completion of the sale, the chief executive officer directly owned 1,234,624 shares in the company, valued at approximately $82,682,769.28. This trade represents a 10.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 1.88% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Wall Street Zen cut Hologic from a “buy” rating to a “hold” rating in a report on Wednesday, October 1st. Stephens restated an “overweight” rating and issued a $78.00 price target on shares of Hologic in a report on Thursday, September 18th. Citigroup upgraded Hologic from a “neutral” rating to a “buy” rating and upped their price target for the stock from $60.00 to $80.00 in a report on Wednesday, July 9th. Evercore ISI set a $78.00 price target on Hologic and gave the stock an “outperform” rating in a report on Tuesday, October 7th. Finally, UBS Group upped their price target on Hologic from $65.00 to $70.00 and gave the stock a “neutral” rating in a report on Thursday, July 31st. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $80.15.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.